BridgeBio Pharma (BBIO) Liabilities and Shareholders Equity (2018 - 2026)

BridgeBio Pharma has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $1.4 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.4 billion, up 55.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 billion (up 34.51% YoY), and the FY2025 annual result was $936.0 million, up 1.82% from the prior year.
• Liabilities and Shareholders Equity came in at $1.4 billion for Q1 2026 at BridgeBio Pharma, up from $936.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q1 2026 to a low of $503.7 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $813.1 million (2022), against an average of $814.9 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 41.59% in 2023 and jumped 68.26% in 2024, its largest moves.
• BridgeBio Pharma's Liabilities and Shareholders Equity stood at $623.0 million in 2022, then declined by 12.3% to $546.4 million in 2023, then surged by 68.26% to $919.3 million in 2024, then rose by 1.82% to $936.0 million in 2025, then jumped by 46.47% to $1.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q1 2026), $936.0 million (Q4 2025), and $998.2 million (Q3 2025), per Business Quant data.